Adimmune slides into red on rising R&D expenditure

Adimmune slides into red on rising R&D expenditure
By Kao Shih-ching / Staff reporter
Vaccine maker Adimmune Corp (國光生技) yesterday reported a net loss of NT$249 million (US$8.91 million) for last quarter, compared with a net profit of NT$1.24 billion in the fourth quarter of last year, due to rising research and development (R&D) expenses that involved a phase 1 clinical trial for its experimental vaccine against COVID-19.
That translates into a loss per share of NT$0.58, widening from minus-NT$0.05 a year earlier.
Revenue last quarter sank 98 percent year-on-year to NT$6.9 million due to a high comparison base last year, it said.

Related Keywords

Brunei ,China ,Malaysia ,Indonesia ,Singapore ,Turkey ,Chinese , ,Adimmune Corp ,Shenzhen Techdow Pharmaceutical Co ,National Health Research Institute On ,Kao Shih Ching ,National Health Research Institute ,Middle Eastern ,台北時報 ,The Taipei Times ,புருனே ,சீனா ,மலேசியா ,இந்தோனேசியா ,சிங்கப்பூர் ,வான்கோழி ,சீன ,காவ் ஷிஹ் சிங் ,தேசிய ஆரோக்கியம் ஆராய்ச்சி நிறுவனம் ,நடுத்தர கிழக்கு ,தி தைப்பே முறை ,